Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study

Ishikawa H., Oka K., Inoue H.

2026
Japanese Journal of Ophthalmology

View publication

Therapeutic Area

Front of the eye (FOTE)
Categories

Clinical development

Affiliations

Orthoptics and Visual Sciences, Kitasato University School of Allied Health Sciences, Kanagawa, Japan; Santen Pharmaceutical Co., Ltd, 4-20 Ofuka-cho, Kita-ku, Osaka, 530-8552, Japan. koji.oka@santen.com; Santen Pharmaceutical Co., Ltd, 4-20 Ofuka-cho, Kita-ku, Osaka, 530-8552, Japan.

Related Publications

Tear Biomarkers of Topical Sirolimus in Meibomian Gland Dysfunction: A Randomized Trial

Zhou L.; Shimizu H.; Togashi Y.; Kirihara T.; Yang Y.; Lam C.T.; Shimada H.; Tong L.

Layer-by-layer tear film measurement in patients with dry eye and meibomian gland dysfunction

Arita R., Takeuchi G., Sasai K., Nakamura M., Akiba M.

Multimodal Approach in Dry Eye Disease Combining In Vivo Confocal Microscopy and HLA-DR Expression

Blautain, B.; Rabut, G.; Dupas, B.; Riancho, L.; Liang, H.; Luzu, J.: Labbé, A.; Garrigue J.-S.; Brignole-Baudouin, F.; Baudouin, C.; Kessal, K.

View all Front of the eye (FOTE) publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022